Zydus Wellness Q1 FY27: PAT down 7% YoY to ₹119 Cr as CCL costs squeeze margins

On a consolidated basis (primary), Zydus Wellness reported revenue of ₹1,437.0 Cr, up 66.9% YoY but down 3.2% QoQ, while PAT fell 7.0% YoY to ₹118.9 Cr and 26.6% QoQ from ₹162.0 Cr. The headline revenue jump is not organic growth — it reflects the full-quarter consolidation of Comfort Click Limited (CCL), acquired August 29, 2025, which the year-ago quarter did not carry at all. Notably, PBT actually rose 11.6% YoY to ₹162.1 Cr, so the entire PAT decline traces to items below the operating line. NPM compressed to 8.3% from 14.8% YoY (10.9% QoQ) and OPM to 16.8% from 18.1% YoY (18.2% QoQ, using PBT-before-exceptionals less other income, plus finance cost and depreciation, over revenue — consistent with the margin convention in our records). The compression is driven by finance costs of ₹26.3 Cr (vs ₹2.5 Cr a year ago, a 10x jump) and depreciation/amortisation of ₹57.1 Cr (vs ₹10.8 Cr, ~5x) — both a direct consequence of CCL acquisition debt funding and PPA-related intangible amortisation. Separately, the effective tax rate rose sharply to 26.7% from 12.0% YoY, because a ₹4.6 Cr net MAT-credit-reversal benefit that lifted last year's quarter did not repeat this quarter (Note 6). Adjusting for that one-off tax item on a like-for-like basis, PAT would have been down only ~3.6% YoY rather than the reported 7.0% — meaning roughly half the headline PAT decline is a tax-benefit base effect, not a fresh operating deterioration, though margin compression from CCL financing/amortisation is real and structural for now. No formal analyst consensus for this specific quarter was found in a web search, so vs-street is unknown. On guidance: the FY26-Q4 call reiterated a medium-to-long-term aspiration of 17-18% EBITDA margin and flagged short-term weather-related headwinds for seasonal brands with an expected recovery — this quarter's 16.8% OPM remains below that band, and revenue was down sequentially rather than showing the flagged recovery, a miss against that qualitative bar. No press release/MD&A accompanied this filing (management framing not extracted), but the filing's own Note 4 states Group revenue and profit are seasonally skewed toward Q1 and Q4 — despite Q1 being a stated peak quarter, PAT still fell 26.6% QoQ, mostly via costs/tax rather than topline (revenue was down just 3.2% QoQ). The standalone (India) business, a cleaner read on the base business, grew steadily: revenue ₹153.0 Cr (+8.6% YoY) and PAT ₹5.5 Cr (+19.6% YoY). Among this quarter's other developments, the company incorporated a new UAE subsidiary (June 30, 2026), continuing its Middle East footprint alongside existing Zydus Wellness General Trading DWC-LLC and Zydus Wellness Trading LLC entities, and its Head of Sales resigned (July 3, 2026) — a governance item worth tracking but with no numbers attached yet; a Polish subsidiary was fined PLN 54,000 for a tax filing delay, an immaterial amount. Going into Q2 FY27, the print sets up a test of whether CCL's finance/amortisation drag moderates as integration matures, whether the MAT-credit tax benefit (absent this quarter) resumes, and whether the seasonal-brand recovery management flagged in May 2026 shows up in the numbers rather than remaining a stated expectation.